Last reviewed · How we verify
latanoprost 0.005% (drug)
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | latanoprost 0.005% (drug) |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Prostaglandin F receptor agonist |
| Target | FP receptor (prostaglandin F receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost binds to prostaglandin F receptors in the eye and enhances drainage of fluid through the uveoscleral (unconventional) pathway. This increased aqueous humor outflow leads to a reduction in intraocular pressure, which is the primary pathogenic mechanism in glaucoma and ocular hypertension. The drug is administered as a topical ophthalmic solution.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation (darkening)
- Conjunctival hyperemia (redness)
- Eyelash growth (hypertrichosis)
- Eye irritation or discomfort
- Periocular skin darkening
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- latanoprost 0.005% (drug) CI brief — competitive landscape report
- latanoprost 0.005% (drug) updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI